Water Vapor Ablation for Prostate Cancer: Long-Term Registry

The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Sex eligibility

Male

Study type

Observational

Primary location

The Urology Place, Inc., San Antonio, Texas, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.
Participant is willing and able to provide written informed consent.

Exclusion criteria

Contraindications per the Vanquish IFU
Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.

Treatment and study plan

Vanquish Therapy

Device

The Francis Medical, Inc. Vanquish Water Vapor Ablation Device ("Vanquish" or "Vanquish System") is a transurethral thermal water vapor ablation device. The Vanquish System is designed ablate prostate tissue, while minimizing side effects.

Primary outcomes

Primary Efficacy Outcome

Time frame: Through study completion, or up to 15 years.

Freedom from disease specific mortality.
Primary Safety Outcome

Time frame: Through study completion, or up to 15 years
Rate of complications classified as Clavien-Dindo grades III-V and attributable to the Vanquish procedure and/or device over time.
- Grade III: Complications requiring surgical intervention (IIIa: laparoscopic, IIIb: open).
- Grade IV: Life-threatening complications (IVa: single organ failure, IVb: multi-organ failure).
- Grade V: Death of a patient.

Study contacts

Contact information is provided by the study sponsor or research team.

Garrett Grenier

CONTACT

[email protected]

763-453-9404

Sydney Cartie

CONTACT

[email protected]

6122866855

Sponsors and collaborators

Lead sponsor

Francis Medical Inc.

Industry

Registry information

Official study title

Vanquish® Water Vapor Ablation for PrOstate CanceR: Long-Term Registry

Acronym: VAPOR-LTR

Important dates

Study start: 2026
Primary completion: 2041
Study completion: 2041
First posted: Mar 6, 2026
Registry last updated: Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting